Showing 961-970 of 3201 results for "".
Triple Threat
https://practicaldermatology.com/topics/general-topics/triple-threat/20629/In defense of the Aron Regimen for resistant atopic dermatitis.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muTargeting the OX40 Pathway
https://practicaldermatology.com/issues/october-2025/targeting-the-ox40-pathway/39764/A Promising New Avenue in Atopic DermatitisComorbidities in Atopic Dermatitis
https://practicaldermatology.com/issues/october-2025/comorbidities-in-atopic-dermatitis/39756/In this article, as part of a series on comorbidities associated with immune-mediated skin diseases, we explore the spectrum of comorbidities linked to AD.Beyond the Flare: Choosing the Right Systemic in Moderate-to-Severe Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/beyond-the-flare-choosing-the-right-systemic-in-moderate-to-severe-atopic-dermatitis/39728/Staphylococcus aureus Colonization
https://practicaldermatology.com/issues/september-2025/staphylococcus-aureus-colonization/37626/In a recent review article, Piewngam and Otto examined the epidemiology, mechanisms, and clinical implications of Staphylococcus aureus (S. aureus) colonization, while evaluating both current and emerging strategies for decolonization.Marketing Leading Technologies That Support Your Team
https://practicaldermatology.com/issues/august-2025/marketing-leading-technologies-that-support-your-team/36708/From ChatGPT and other artificial intelligence (AI) platforms to the latest mobile apps, technology continues to transform the already dynamic field of health care.Psoriasis Update: Current State, Pipeline, and More
https://practicaldermatology.com/issues/july-2025/psoriasis-update-current-state-pipeline-and-more/36509/April W. Armstrong, MD, MPH, has been a driving force behind advancements in psoriasis treatments in recent years. A professor and chief of dermatology at University of California Los Angeles, Dr. Armstrong has served in leadership positions for the National Psoriasis Foundation, International PsoriIn The Pipeline: Phase 1, 2, and 3
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/pipeline-phase-1-2-and-3/29087/This summary provides the latest news on of some of the recent Phase 1, Phase 2, and Phase 3 clinical studies for psoriasis treatments.Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/annual-trends-in-medicare-part-d-prescription-claims-for-guselkumab-20182020/28861/Jachin Wu, MD, FAAD, and colleagues talk about Medicare claims for guselkumab